Immunophenotype and karyotype data before and after disease progression in 8 cases
| Case no. . | Diagnosis . | Blasts, %7-150 . | CD34 . | CD7 . | CD10 . | CD15 . | CD117 . | Karyotype . |
|---|---|---|---|---|---|---|---|---|
| 127 | RA | 88 | 94.6 | < 10 | 16.5 | ND | ND | 44,XY,del(5)(q13q33),add(11)(q13),−13, add(13)(p11),−19,del(20)(q11)[4]/45, idem,+mar[4]/46,idem,+2mar[1] |
| 127 | AL-MDS | 97 | 90.7 | < 10 | 12.2 | 18.2 | < 10 | 46,XY,del(5)(q13q33),add(11)(q13),−13, add(13)(p11),−19,del(20)(q11), +2mar[11]/45,idem,−21[1]/45,idem,−mar[1]/46,XY[2] |
| 118 | CMML | 90 | 94.4 | < 10 | < 10 | < 10 | 95.6 | 46,XY[20] |
| 118 | RAEB-t | 98 | 98.1 | < 10 | < 10 | < 10 | 96.9 | 46,XY[20] |
| 49 | RAEB | 69 | 70.8 | < 10 | 33.3 | 52.3 | 52.5 | 46,XX[14]/47,XX,+14[4]/47XX,+9[2] |
| 49 | AL-MDS | 100 | 99.7 | < 10 | < 10 | < 10 | 92.4 | 46,XX[20] |
| 45 | RAEB-t | 36 | 88.4 | < 10 | 21.4 | 39.9 | 53.4 | 46,XX[20] |
| 45 | AL-MDS | 93 | 97.7 | < 10 | 43.2 | 11.0 | 44.7 | 46,XX[20] |
| 80 | RAEB-t | 90 | 93.8 | 21 | 15.3 | 20.6 | 82.9 | 47,XY+8[18]/48,XY,+8,+9[2] |
| 80 | AL-MDS | 94 | 98.7 | 16.9 | < 10 | 28.4 | 81.9 | 47,XY,+8[19]/48,XY,+8,+9[1] |
| 6 | RAEB | 58 | 95.6 | < 10 | 11.4 | 23.9 | 28.6 | 43,XY,del(5)(q23q32),add(6)(p21),−7, add(12)(p12),−20,−21[9]/Others[11] |
| 6 | RAEB-t | 98 | 96.6 | 28 | < 10 | 20.3 | 43.0 | No data |
| 116 | RAEB-t | 50 | 92.6 | < 10 | 15.3 | 54.7 | 12.1 | 46,XX[5]/45,XX,14q+,−16[1] |
| 116 | AL-MDS | 96 | 91.8 | 78 | 19.8 | 25.0 | < 10 | 46,XX,add(14)(q32)[19]/47,XX,+8, add(14)(q32)[1] |
| 461 | RAEB | 77 | 14.4 | < 10 | 16.5 | 39.6 | 28.0 | 46,XX[8]/46,XX,del(8)(p11)[1] |
| 462 | RAEB | 53 | 78.5 | 38 | 17.0 | 35.8 | 29.3 | 46,XX[39]/44,XX,del(1)(p31),−16,−19[1] |
| 463 | AL-MDS | 95 | 99.3 | 84 | < 10 | 10.4 | 35.7 | 44,XX,−7,der(12;17)(q10;q10)[5] |
| Case no. . | Diagnosis . | Blasts, %7-150 . | CD34 . | CD7 . | CD10 . | CD15 . | CD117 . | Karyotype . |
|---|---|---|---|---|---|---|---|---|
| 127 | RA | 88 | 94.6 | < 10 | 16.5 | ND | ND | 44,XY,del(5)(q13q33),add(11)(q13),−13, add(13)(p11),−19,del(20)(q11)[4]/45, idem,+mar[4]/46,idem,+2mar[1] |
| 127 | AL-MDS | 97 | 90.7 | < 10 | 12.2 | 18.2 | < 10 | 46,XY,del(5)(q13q33),add(11)(q13),−13, add(13)(p11),−19,del(20)(q11), +2mar[11]/45,idem,−21[1]/45,idem,−mar[1]/46,XY[2] |
| 118 | CMML | 90 | 94.4 | < 10 | < 10 | < 10 | 95.6 | 46,XY[20] |
| 118 | RAEB-t | 98 | 98.1 | < 10 | < 10 | < 10 | 96.9 | 46,XY[20] |
| 49 | RAEB | 69 | 70.8 | < 10 | 33.3 | 52.3 | 52.5 | 46,XX[14]/47,XX,+14[4]/47XX,+9[2] |
| 49 | AL-MDS | 100 | 99.7 | < 10 | < 10 | < 10 | 92.4 | 46,XX[20] |
| 45 | RAEB-t | 36 | 88.4 | < 10 | 21.4 | 39.9 | 53.4 | 46,XX[20] |
| 45 | AL-MDS | 93 | 97.7 | < 10 | 43.2 | 11.0 | 44.7 | 46,XX[20] |
| 80 | RAEB-t | 90 | 93.8 | 21 | 15.3 | 20.6 | 82.9 | 47,XY+8[18]/48,XY,+8,+9[2] |
| 80 | AL-MDS | 94 | 98.7 | 16.9 | < 10 | 28.4 | 81.9 | 47,XY,+8[19]/48,XY,+8,+9[1] |
| 6 | RAEB | 58 | 95.6 | < 10 | 11.4 | 23.9 | 28.6 | 43,XY,del(5)(q23q32),add(6)(p21),−7, add(12)(p12),−20,−21[9]/Others[11] |
| 6 | RAEB-t | 98 | 96.6 | 28 | < 10 | 20.3 | 43.0 | No data |
| 116 | RAEB-t | 50 | 92.6 | < 10 | 15.3 | 54.7 | 12.1 | 46,XX[5]/45,XX,14q+,−16[1] |
| 116 | AL-MDS | 96 | 91.8 | 78 | 19.8 | 25.0 | < 10 | 46,XX,add(14)(q32)[19]/47,XX,+8, add(14)(q32)[1] |
| 461 | RAEB | 77 | 14.4 | < 10 | 16.5 | 39.6 | 28.0 | 46,XX[8]/46,XX,del(8)(p11)[1] |
| 462 | RAEB | 53 | 78.5 | 38 | 17.0 | 35.8 | 29.3 | 46,XX[39]/44,XX,del(1)(p31),−16,−19[1] |
| 463 | AL-MDS | 95 | 99.3 | 84 | < 10 | 10.4 | 35.7 | 44,XX,−7,der(12;17)(q10;q10)[5] |
Immunophenotype data are the percentage of positive cells.
For case 46, the immunophenotype was determined 3 times: at the time of initial diagnosis of RAEB (461), 1 year later when the diagnosis was still RAEB but cytopenia had progressed (462), and at the time of disease progression to AL-MDS (463).
ND indicates not determined.
The percentage of blasts in samples used for FCM.